| Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment (NCT07460206) | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-08-01 |
| Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma (NCT07460245) | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-06-01 |
| A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer (NCT07418931) | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-05-01 |
| Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients (NCT07363252) | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-04-14 |
| A Prospective Observational Study on of Early-Onset Gastrointestinal Cancer: From Tumor Features to Patient Lifestyle Habits (NCT07479472) | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-04-01 |
| XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients (NCT07381777) | Gruppo Oncologico Italiano di Ricerca Clinica | 2026-01-31 |
| Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC (NCT07356544) | Gruppo Oncologico Italiano di Ricerca Clinica | 2025-08-12 |
| Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). (NCT06663098) | Gruppo Oncologico Italiano di Ricerca Clinica | 2025-01-24 |
| Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib (NCT06548867) | Gruppo Oncologico Italiano di Ricerca Clinica | 2024-05-28 |
| AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (NCT06464068) | Gruppo Oncologico Italiano di Ricerca Clinica | 2024-01-16 |
| Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (NCT06418087) | Gruppo Oncologico Italiano di Ricerca Clinica | 2022-05-27 |
| Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (NCT04996017) | Gruppo Oncologico Italiano di Ricerca Clinica | 2021-12-14 |
| Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (NCT05015010) | Gruppo Oncologico Italiano di Ricerca Clinica | 2021-05-20 |
| Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer (NCT04612309) | Gruppo Oncologico Italiano di Ricerca Clinica | 2020-10-28 |
| Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer (NCT04730999) | Gruppo Oncologico Italiano di Ricerca Clinica | 2020-07-01 |
| Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NCT04072198) | Gruppo Oncologico Italiano di Ricerca Clinica | 2019-09-26 |
| Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy (NCT04072068) | Gruppo Oncologico Italiano di Ricerca Clinica | 2019-06-27 |
| Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) (NCT03976518) | Gruppo Oncologico Italiano di Ricerca Clinica | 2019-05-07 |
| Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer (NCT03627728) | Gruppo Oncologico Italiano di Ricerca Clinica | 2018-06-13 |
| Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial) (NCT03542461) | Gruppo Oncologico Italiano di Ricerca Clinica | 2017-09-25 |
| Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma (NCT03469713) | Gruppo Oncologico Italiano di Ricerca Clinica | 2017-07-14 |
| Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC (NCT03219762) | Gruppo Oncologico Italiano di Ricerca Clinica | 2017-02-07 |
| A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM (NCT03560973) | Gruppo Oncologico Italiano di Ricerca Clinica | 2016-12-22 |
| Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients (NCT03144947) | Gruppo Oncologico Italiano di Ricerca Clinica | 2016-11-29 |
| Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin (NCT02687958) | Gruppo Oncologico Italiano di Ricerca Clinica | 2015-05-01 |
| Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NCT02109341) | Gruppo Oncologico Italiano di Ricerca Clinica | 2014-02-01 |
| Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC (NCT00786331) | Gruppo Oncologico Italiano di Ricerca Clinica | 2007-07-01 |
| Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. (NCT00502034) | Gruppo Oncologico Italiano di Ricerca Clinica | 1994-07-01 |